Patients with platinum-resistant ovarian cancer face a grim prognosis, with an average survival of around one year after diagnosis. A new study has discovered that those who took relacorilant alongside standard treatment lived four months longer than women receiving usual care. The study on relacorilant examined data on 381 platinum-resistant ovarian cancer patients, and researchers established that those taking relacorilant were 35% less likely to die compared to those receiving standard care.
According to the authors, these outcomes position relacorilant plus nab-paclitaxel as a new standard treatment option for patients with platinum-resistant ovarian cancer. The research team added that this regimen should support this regimen as a new standard of care. A separate study suggests that an immunotherapy cancer drug can improve survival odds among women with platinum-resistant ovarian cancer.
Immunotherapy works by stimulating the body's immune system to fight cancer cells, and researchers sought to establish whether administering pembrolizumab alongside standard care would prove beneficial for platinum-resistant ovarian cancer patients. 7 months, while those who received standard care alone lived an average of 14 months. Relacorilant is a medication originally used to treat Cushing's syndrome, and it may help extend the lives of ovarian cancer patients.
This repurposing highlights a growing trend in oncology where existing drugs are tested for new applications, potentially speeding up treatment availability. Key unknowns remain regarding the accessibility and long-term impacts of these treatments. The specific side effects or risks associated with relacorilant for ovarian cancer patients have not been detailed in the studies, nor have those for pembrolizumab.
How widely available or accessible relacorilant and pembrolizumab are for ovarian cancer treatment is unclear, as is the cost and whether they are covered by insurance or healthcare systems. Additionally, the long-term survival rates beyond the average months reported in these studies are not yet known, leaving questions about durability and quality of life improvements.